Back to first-pass browser

First-pass extracted concept

HLA-DR

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

HLA-DR is used here as a tumor expression feature linked to immune context and prognosis in LUAD. HLA-DR-strong tumors showed higher ICOS-positive TIL density.

Source 1DOIPubMed

Resources required

The study assessed tumor HLA-DR status in resected LUAD specimens by immunohistochemistry.

Source 1DOIPubMed

What problem it solves

It helps identify tumors with a more favorable immune context and longer recurrence-free survival.

Source 1DOIPubMed

What it does not solve

The abstract does not show whether HLA-DR is independently prognostic after multivariable adjustment.

Source 1DOIPubMed

Alternatives

The paper evaluates HLA-DR alongside HLA class I and TIL subset densities.

Source 1DOIPubMed

Evidence Snippets

ICOS+ TIL density was significantly higher in HLA-DR-strong tumors, and tumor HLA class I and HLA-DR were associated with longer recurrence-free survival.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1associationsupports2026Source 1DOIPubMed

ICOS-positive tumor-infiltrating lymphocyte density was significantly higher in HLA-DR-strong tumors.

Quoted textsource-backed
ICOS+ TIL density was significantly higher in HLA-DR-strong tumors
Claim 2context dependent associationmixed2026Source 1DOIPubMed

Among HLA-DR-strong tumors, ICOS-high patients tended toward longer cancer-specific survival.

Quoted textsource-backed
among HLA-DR-strong tumors, ICOS-high patients tended toward longer cancer-specific survival
Claim 3prognostic associationsupports2026Source 1DOIPubMed

Tumor HLA class I and HLA-DR expression were associated with longer recurrence-free survival in lung adenocarcinoma.

Quoted textsource-backed
tumor HLA class I and HLA-DR were associated with longer recurrence-free survival